Eli Lilly (LLY) rated Sell/Avoid: overvaluation, slowing GLP-1 growth, Novo competition, bearish technicals and insider ...
February fiscal flows added a $360B+ private sector surplus, boosting liquidity and risk assets; Fed near peak rates.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果